Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson RA.
Eufemon Cereno R, et al. Among authors: jiang w.
Radiother Oncol. 2023 May;182:109576. doi: 10.1016/j.radonc.2023.109576. Epub 2023 Feb 22.
Radiother Oncol. 2023.
PMID: 36822355
Clinical Trial.